updated 1/7/2011 7:16:51 AM ET 2011-01-07T12:16:51

DALLAS, Jan. 7, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Lexicon Pharmaceuticals Inc. (Nasdaq:LXRX). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/lp/LXRX

Lexicon Pharmaceuticals Inc. (LXRX) is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. It has currently four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis. LXRX has used its proprietary gene knockout technology to identify more than 100 promising drug targets. The Company has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.

For only $19 a month, you can sign up for our real-time stock alert service. Click here to join now: http://www.pennystocklive.com/premium-membership/

In the report, the analyst notes:

"Shares of LXRX jumped Thursday after the Company reported its key drug for type-2 diabetes, LX4211, had shown encouraging data in a mid-stage study. The Company said a new tablet formulation of LX4211 worked as well as or better than a liquid formulation used in previous clinical trials. The drug's liquid version had already shown promising results in a mid-stage study last year.

"The recent study showed that the oral version of the said drug significantly increased the presence of GLP-1, an important peptide that mediates insulin and glucagon secretion."

To read the entire report visit: www.microstockprofit.com/lp/LXRX

See what investors are saying about LXRX at http://www.stockhideout.com

Get breaking news on LXRX at http://thestockmarketwatch.com/

MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.

CONTACT: Brian Johnson
         info@microstockprofit.com
         1-888-307-2850

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 4.94%
$30K home equity loan FICO 5.19%
$75K home equity loan FICO 4.58%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.40%
13.40%
Cash Back Cards 17.92%
17.91%
Rewards Cards 17.12%
17.11%
Source: Bankrate.com